SPC326
Lefamulin, sölt og lausnarsambönd þess
Status:
VeittApplication date:
11.1.2021Application published:
15.2.2021Grant published:
15.6.2022
Max expiry date:
18.3.2033Medicine name:
XenletaMedicine for children:
No
Timeline
Today
11.1.2021Application
15.2.2021Publication
15.6.2022Registration
18.3.2033Expires
Marketing license
IS authorization number:
EU/1/20/1457/001; EU/1/20/1457/002Date:
11.8.2020
Foreign authorization number:
EU/1/20/1457Date:
27.7.2020
Owner
Name:
Nabriva Therapeutics GmbHAddress:
Leberstraße 20, Wien AT
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2137143